

induced fluorescence. Parallel processing speeds up handling and improves reproducibility. Picomolar concentrations can be quantified at precision levels ~ 5-10% CV. Miniaturization reduces volume requirements for sample and reagent. A protein is quantified using $<1 \mu\text{l}$ of sample. Potentially >10 different proteins could be quantified simultaneously from a $20 \mu\text{l}$ sample, increasing information content and providing results within hours.

75.31

Role of macrophages in traumatic skeletal muscle injury

Mukesh Summan, Tracy Hulderman, Joanna M Matheson, Petia P Simeonova, Toxicology and Molecular Biology, DHHS/CDC/NIOSH, 1095 Willowdale Road, Morgantown, WV 26505

Traumatic skeletal muscle injuries result in profound histopathological changes and loss of muscle function. These injuries are associated with local infiltration of large numbers of mononuclear cells, degeneration of injured myofibres and phagocytic removal of cell debris. In the present study we evaluated the role of systemic macrophages in the injury/repair mechanisms in a traumatic skeletal muscle injury model using liposome encapsulated clodronate, a drug with well characterized monocyte/macrophage depleting qualities. C57BL/6 mice ($n = 4$ per group) were injected with clodronate liposomes 48 and 2 hours prior to the freeze injury of the left tibialis anterior (TA) muscle and every third day during the post-injury period. Control mice received phosphate buffered saline (PBS) liposomes. At 1, 3 or 9 days post-injury, the TA muscles were harvested for histology or gene expression evaluation by quantitative real time RT-PCR. Histopathological examination revealed less inflammatory cell infiltration in the injured muscles of clodronate treated mice at day 3 post-injury and delayed muscle tissue recovery with an impaired clearance of the necrotic myofibers at day 9 post-injury. Furthermore, macrophage depletion significantly attenuated injury-induced inflammatory cytokine and growth factor mRNA expression, for example tumor necrosis factor α , when compared to the PBS-liposome treated mice. These findings define the role of macrophages and the related cytokines as critical components of the complete recovery from skeletal muscle traumatic injury.

75.32

Reversal of Erosive Changes with Addition of Infliximab to Standard Therapy in Rheumatoid Arthritis

David H Snow, Carolina Arthritis Associates, PA, 1710 S. 17th Street, Wilmington, NC 28401

Infliximab (IFX) in combination with methotrexate (MTX) significantly improves signs and symptoms of rheumatoid arthritis (RA), improves physical function and inhibits progression of structural joint (JT) damage. We describe reversal of erosive (ERO) changes when IFX was added to standard therapy (TX) in a refractory RA patient (pt). A 67 year old white male with a 3yr history of RA had impressive synovitis of metacarpophalangeal (MCP), proximal interphalangeal (PIP) and subtalar JT, wrists, ankles, and knees. Radiographic (RG) evidence revealed extensive ERO changes of PIP, joint space narrowing (JSN) of MCP, and erosions of IP. Previous TX with prednisone (GC), NSAIDS, HCQ, MTX, Aurothioglucose (AU), and SSZ proved inadequate. Synovitis and elevated ESR persisted with increasing weekly doses of MTX. After 3 infusions of 3mg/kg IFX, synovitis of MCP and PIP resolved and fist function was restored to normal. After 2 years, pt continues to receive 5.6 mg/kg IFX q8 wk with no serious infusion reactions or serious adverse events. Au TX was discontinued, GC and MTX doses decreased. Pt shows no evidence of synovitis in hands, wrists, feet, or knees. Repeat RG evaluations show healing of ERO changes and JSN of PIP, right first IP, and restoration of ulnar styloid process. Pt reports marked improvement in quality of life and physical function. This case report suggests that IFX added to standard combination therapy may promote reversal and healing of those erosive changes.

75.33

Interleukin 6 indirectly induces migration of cultured epidermal cells from IL-6 deficient mice

Randle Michael Gallucci, Dusti K Sloan, Anne B Murray, Sijy J O'Dell, Pharmaceutical Sciences, University of Oklahoma, P.O. Box 26901, Oklahoma City, OK 73190

We have previously shown that IL-6 deficient transgenic mice (IL-6KO) display significantly delayed cutaneous wound healing compared to wild type control animals, requiring up to three fold longer to heal. While the necessity of inflammation during wound healing has been well established, the role of IL-6 in this process has not. To further describe the role of IL-6 in skin wound healing, an in vitro model was developed utilizing cultured dermal keratinocyte and epidermal fibroblast cells from neonatal IL-6KO mice. This system allows for the direct assessment of the effects of IL-6 on skin cells without the confounding presence of endogenous IL-6. Using a transwell migration assay, we have found that IL-6 appears to significantly induce cell motility in cultured IL-6KO keratinocytes (up to 5 fold) when cultured in the presence of dermal fibroblasts. In addition to these functional data, results from gene array analysis of IL-6 treated fibroblasts indicate that IL-6 does not appear to modulate any known soluble keratinocyte migratory factors. These data indicate that a likely mechanism by which IL-6 can modulate wound healing is by stimulating the migration of keratinocytes indirectly through the production of an as yet unidentified soluble fibroblast derived factor.

75.34

Automation of intracellular cytokine staining for flow cytometry

Laurel Nomura¹, Holden T. Maecker¹, Pierre Bierre², ¹BD Biosciences, Immunocytometry Systems, 2350 Quince Dr, San Jose, CA 95131, ²PB Consulting, pbierre@attbi.com

Flow cytometric analysis of intracellular cytokine responses offers a way to measure immune function within specific cell types (e.g. CD4, CD8 T-cells). After activation of whole blood samples, cells are prepared for cytokine flow cytometry (CFC) by lysing, centrifugation washing, permeabilizing, rewashing, staining with mAb, and washing again. Our goal was to adapt a commercially available, cell-washing test-tube robot, BD Biosciences' Lyse/Wash Assistant (LWA), to automate these sample preparation steps. The LWA with Intracellular Option handles all the above steps except mAb dispensing. The LWA first runs a *pre-staining protocol*, which performs cell lysis and permeabilization. Samples are then removed for manual mAb addition. Finally, the samples go back on the LWA for a *post-staining protocol*, which times the mAb incubation and performs a final wash, outputting analysis-ready cells. Equivalency with the manual CFC method was established through regression analysis on two key results variables: percent of CD69+ cytokine+ cells, and population mean signal-to-noise. Lab worker hands-on time was reduced by about 80%. The LWA is very simple to operate, and with a few modifications for intracellular staining, offers a low-cost method for standardizing sample preparation of cytokine flow cytometry assays. Research supported by BD Biosciences, Immunocytometry Systems.

75.35

Role of CCL3 in Protective Antiviral Immunity

John M Dye¹, Allan J. Zajac², Daniel G Quinn¹, ¹Microbiology & Immunology, Loyola University, 2160 South First Avenue, Maywood, IL 60153, ²Microbiology, Univ. of Alabama at Birmingham, Birmingham, AL

We have shown that mice deficient in the chemokine CCL3 or its receptors fail to develop protective immunity against secondary intracranial (i.c.) infection with lymphocytic choriomeningitis virus (LCMV). Immunostaining of brain sections revealed no difference between the accumulation or localization of CD8 cells in the brains of i.c. infected CCL3-deficient mice compared with B6 mice. This suggests that the failure of CCL3-deficient mice to control the infection is not due to a failure of the CD8 cells to localize to the infected CNS. By flow cytometry we found that all of the LCMV-specific CD8 cells and approximately half of the LCMV-specific CD4 cells express CCL3. We investigated whether CCL3 production by infiltrating immune cells

The American Association of Immunologists
90th Anniversary Annual Meeting

Immunology 2003
Denver, Colorado
May 6 – 10, 2003

APR 23 2003

ABSTRACTS 29.1 – 162.31

Indexes
Key Word
Author

The American Association of Immunologists

American Association of Veterinary
Immunologists

American Society of Transplantation
Association of Medical Laboratory

Immunologists

Canadian Society for Immunology
Clinical Immunology Society

International Society for Interferon and Cytokine
Research

International Society for
NeuroImmunoModulation

International Society of Neuroimmunology

PsychoNeuroImmunology Research Society

Society for Leukoctye Biology

Society for Mucosal Immunology

Society for Natural Immunity

THE FASEB JOURNAL

Volume 17, Number 7

April 14, 2003

ABSTRACTS

WEDNESDAY

May 7, 2003

T Cell Development	C1
Signaling and Costimulation in Allergic Inflammation	C9
Immunopathogenesis of Infection	C15
Vaccine and Immunotherapeutic Strategies against Pathogens	C23
Pathogenic Mechanisms in Autoimmune Disease	C31
Animal Models of Autoimmune Disease	C38
Regulation of Leukocyte Migration and Inflammation in Disease	C43
Host Defense and Innate Immunity	C50
Transplantation Immunology I	C58
Signaling of Chemokines and Cytokines	C65
Molecular Regulation of Inflammation	C70
Anti-tumor Effector Cells and Regulation of Tumor Immunity	C73
Effector Mechanisms and Regulation of Effector Cells	C79
Protective Mucosal Immune Responses	C85

THURSDAY

May 8, 2003

B Cell Development and Activation	C88
Transcriptional Regulation of the Immune System	C97
Regulation of Lymphocyte Migration and Tissue Localization	C104
Fc Receptors, Complement and Acute Phase Proteins	C106
Transplantation Immunology II	C111
The Role of Chemokines and Cytokines	C116
Class I Pathway and CD8 T Cell Recognition	C119
Immunotherapy of Cancer	C122
Non-classical Antigen Presentation Pathways ..	C129
Role of Modulatory Cytokines in Disease Models	C130
Immunomodulation I: Cytokines and Chemokines	C139

Immunomodulation II: Cytokines and Chemokines	C142
Hematopoiesis and Mechanisms of Cell Survival	C147
Innate Immunity against Pathogens	C153
Lymphocyte Responses to Pathogens	C162
Tolerance and Autoimmunity	C174
Costimulation and Autoimmunity	C177
Genetics and Autoimmune Disease	C179
B Cells and Autoantibodies in Pathogenesis of Autoimmunity	C182

FRIDAY

May 9, 2003

Molecular Aspects of Repertoire Formation (Recombination, Isotype Switching, Somatic Mutation)	C190
Host Defense against Parasitic and Fungal Infections	C193
Macrophages and Dendritic Cells	C197
Immune System Regulation: Signal Pathways in B Cell Development, Regulation and Activation	C202
Mechanisms of Costimulation and Tolerance	C210
Immune System Regulation: Signaling Pathways in T Cell Development, Regulation, and Activation	C218
Influences on Mucosal Immunity	C230
Mechanisms of Tumor Rejection and Modulation of Anti-tumor Responses	C235
T Cell Memory and Homeostasis	C240
Development and Regulation of Allergic Disease and Asthma	C248
Anchoring Immunity: Interactions of Pathogens with Antigen Presenting Cells	C255
Regulatory T Cells in Autoimmunity	C258
Regulation of Signal Pathways in Immune Cells	C260
Cytokines and Autoimmune Disease	C269
Immunotherapy	C275

The abstracts on pages C1-C334 were prepared by the authors and printed by photo-offset without change. Abstracts are not subject to scientific review; therefore, the scientific validity of the results reported is the responsibility of the authors and sponsors. Accuracy, form of citation, designation of materials,

acknowledgment of coauthors and of grant support, terminology, nomenclature, and the like, remain the responsibility of the authors and sponsors. The appearance of an abstract in this issue does not necessarily imply future publication of a scientific paper.

Editor-in-Chief
Vincent T. Marchesi
Editorial Associate
Claire S. Veilleux

Associate Editors
Edward J. Goetzl
Yusuf A. Hannun
Joseph A. Madri

Publications and Communications Committee
Alan G. Goodridge (ASBMB)
Sandra R. Wolman (ASIP)
Susan S. Percival (ASNS)
Eleanor S. Metcalf (AAI)
Suse B. Broyde (BPS)
Donald A. Fischman Chair (AAA)
Mark A. Hermodson (Protein)
Marc K. Drezner (ASBMR)
Stephen J. Weiss (ASCI)
Peter H. Byers (ASHG)
Thomas D. Sargent (SDB)
Sidney H. Golub (non-voting)
Ex Officio
Steven L. Teitelbaum
Vincent T. Marchesi
FASEB Society
Executive Officers

Director, FASEB Office of Publications
Nancy J. Rodnan
Senior Editor
Lynn Willis
Copy Editor
Kendall Sites
FJ Express Production Coordinator
Mary Kiorpis Eig
Marketing/Advertising Manager
Jennifer L. Pesanelli
Advertising Account Manager
Susan J. Mergenhenagen
301-634-7103
Fax: 301-634-7153
Subscription Manager
Eleanor B. Peebles
301-634-7029
Fax: 301-634-7099

Editorial Board
Kari Alitalo
Mina J. Bissell
Meredith Bond
David A. Brenner
H. Franklin Bunn
George H. Caughey
Pierre Chambon
Thomas O. Daniel
Balz Frei
Martin E. Hemler
Timothy Hla
Tadamitsu Kishimoto
Hynda K. Kleinman
John S. Lazo
John J. Lemasters
George M. Martin

Mark P. Mattson
Linda C. McPhail
Hideaki Nagase
Lina M. Obeid
Jordan S. Pober
Robert E. Pollack
Stanley B. Prusiner
Russel J. Reiter
Noel R. Rose
Charles N. Serhan
William C. Sessa
Solomon H. Snyder
Andrew P. Somlyo
William G. Stetler-Stevenson
Makoto M. Taketo
George D. Yancopoulos

Editor-in-Chief
Boyer Center for Molecular Medicine
Yale University School of Medicine
295 Congress Avenue, (P.O. Box 9812)
New Haven, CT 06519-1418, USA
Phone: 203-737-2334 Fax: 203-737-2267
email: vincent.marchesi@yale.edu

Editorial Office
Boyer Center for Molecular Medicine
Yale University School of Medicine
295 Congress Avenue (P.O. Box 9812)
New Haven, CT 06519-1418, USA
Phone: 203-737-2334 Fax: 203-737-2267
Email: faseb@yale.edu

Publications Office
The FASEB Journal
9650 Rockville Pike
Bethesda, MD 20814-3998, USA
Phone: 301-634-7100
Fax: 301-634-7809
Email: ksites@faseb.org

The FASEB Journal (ISSN-0892-6638) is published 15 times a year (monthly except three times in March and two times in April) by the Federation of American Societies for Experimental Biology, 9650 Rockville Pike, Bethesda, MD 20814-3998, U.S.A. Copyright © 2003 by FASEB. All rights reserved. Requests for copyrighted material should be made in writing to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. Periodicals postage paid at Bethesda, Maryland, and at additional mailing offices. **Postmaster:** Send change of address to *The FASEB Journal*, 9650 Rockville Pike, Bethesda, MD 20814-3998. The views expressed in articles are those of the authors and not necessarily those of the Federation. Send manuscripts and proposals to the Editor-in-Chief. See **Instructions for Authors** online at <http://www.fasebj.org>.

2003	United States	Canada/Mexico	Rest of World	Online Only
INSTITUTION	\$648.	\$672.	\$710.	\$648.
MEMBER	\$93.	\$113.	\$146.	N/A
INDIVIDUAL	\$159.	\$179.	\$212.	N/A
STUDENT	\$45.	\$65.	\$97.	N/A

Corporate members of FASEB

The American Physiological Society • American Society for Biochemistry and Molecular Biology • American Society for Pharmacology and Experimental Therapeutics
American Society for Investigative Pathology • American Society for Nutritional Sciences • The American Association of Immunologists • Biophysical Society
American Association of Anatomists • The Protein Society • The American Society for Bone and Mineral Research • American Society for Clinical Investigation
The Endocrine Society • The American Society of Human Genetics • Society for Developmental Biology